-
Article
Open AccessCox proportional hazards regression in small studies of predictive biomarkers
Predictive biomarkers are essential for personalized medicine since they select the best treatment for a specific patient. However, of all biomarkers that are evaluated, only few are eventually used in clinica...
-
Article
Open AccessLimiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene signature (MammaPrint) has potential to select patients th...
-
Article
Open AccessA real or apparent decrease in glomerular filtration rate in patients using olaparib?
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. Increased serum creatinine levels have been observed in patients taking olaparib, but the underly...
-
Article
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial
The BRCA1-like profile identifies tumors with a defect in homologous recombination due to inactivation of BRCA1. This profile has been shown to predict which stage III breast cancer patients benefit from myeloabl...
-
Article
Open AccessClinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)
Studies showed that axillary lymph node dissection can be safely omitted in presence of positive sentinel lymph node(s) in breast cancer patients treated with breast conserving therapy. Since the outcome of th...
-
Article
An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome
Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-treated patients. However, tamoxifen itself and other metabolites also show antiestrogenic anti-tumor activity. Therefor...
-
Article
Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1
-
Article
Open AccessThe value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07)
Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It h...
-
Article
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to predict recurrence-free survival (RFS) in triple-...
-
Article
Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen
The anti-estrogenic effect of tamoxifen is suggested to be mainly attributable to its metabolite (Z)-endoxifen, and a minimum therapeutic threshold for (Z)-endoxifen in serum has been proposed. The objective of t...
-
Article
Open AccessOptimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
Clinical guidelines for breast cancer treatment differ in their selection of patients at a high risk of recurrence who are eligible to receive adjuvant systemic treatment (AST). The 70-gene signature is a mole...
-
Article
Prognostic factors for survival in metastatic breast cancer by hormone receptor status
Hormone receptor (HR) status is an important prognostic factor for patients with metastatic breast cancer (MBC) and is also correlated with other prognostic factors, such as initial lymph node status, HER2-Neu...
-
Article
Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
A sensitive and selective HPLC–MS/MS assay was used to analyze steady-state serum concentrations of tamoxifen, N-desmethyltamoxifen (E)-endoxifen, (Z)-endoxifen, N-desmethyl-4′-hydroxytamoxifen, 4-hydroxytamoxife...
-
Article
Open AccessNeoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
Changing the neoadjuvant chemotherapy regimen in insufficiently responding breast cancer is not a standard policy. We analysed a series of patients with ‘luminal’-type breast cancer in whom the second half of ...
-
Article
Open AccessCYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
Estrogen catabolism is a major function of CYP2C19. The effect of CYP2C19 polymorphisms on tamoxifen sensitivity may therefore not only be mediated by a variation in tamoxifen metabolite levels but also by an eff...
-
Article
Open AccessImportance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
The antiestrogenic effect of tamoxifen is mainly attributable to the active metabolites endoxifen and 4-hydroxytamoxifen. This effect is assumed to be concentration-dependent and therefore quantitative analysi...
-
Article
Open AccessIdentification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients....
-
Article
Gene expression profiling in breast cancer – design of a pooled database to address open questions
GRUNDLAGEN: Das Netherlands Cancer Institute hat DNA-microarrays zur Identifizierung eines 70-Gen-Expressionsprofils verwendet, welches ein signifikant kürzeres Intervall bis zur Fernmetastasierung beim Mammak...
-
Article
Validation of 70-gene prognosis signature in node-negative breast cancer
Purpose The 70-gene prognosis signature (van’t Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validatio...
-
Chapter and Conference Paper
Clinical relevance of drug resistance: Where do we stand now and where are we going to ?
While chemotherapy can cure several tumours even in advanced stages, like testicular cancer, several cancers of childhood and some haematological malignancies, and can prolonge survival in a number of other ma...
